Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Saflink Corp. (ESAF) Biometric Software Provider -- Ignore unavailable to you. Want to Upgrade?

To: bob jordan who wrote (4042)	12/6/1998 2:23:00 PM
From: brad greene	Respond to of 4676

Bob, Good post......and OK. bg

To: bob jordan who wrote (4042)	12/6/1998 6:36:00 PM
From: Steve Felix	Respond to of 4676

Bob, I don't think it will matter which API is used. Not counting small or fly by night companies who are trying to throw something together to put on the market, why will companies with pockets and software departments buy high margin software from NRID instead of write their own. I truly can not understand how they expect to market this to substantial companies.

To: bob jordan who wrote (4042)	12/6/1998 7:16:00 PM
From: David	Read Replies (1) \| Respond to of 4676

Let's assume you are right about HAAPI and BioAPI compatibility . . . It still would be big trouble for NRID, which needs business in the door ASAP. HAAPI is apparently a fairly primitive API, or at least an API that doesn't address all cross-application issues. Presumably, BioAPI is more ambitious, and worth waiting for. Assuming that SAF software can be conformed to BioAPI standards, it happens after the BioAPI is out there for everyone to use. (And maybe after the BioAPI "founders" have their shot first.) To the extent NRID has a head start on software (although it doesn't seem to be leading anywhere commercially), their advantage would be gone. The next SAF, BioAPI-compliant product will be racing to market against software from Identix/Identicator, I/O Software, and who knows who else. Some of these competitors will be better funded, and any of them could come up with equivalent or better products. What is NRID's hope for surviving in that environment, in the financial shape it is in already? Worse, with the overhanging API about to hit, NRID software sales on its present inventory would be frozen . . . and they certainly can't afford that outcome. I think my earlier advice is still good. David (And I managed to write this analysis without any personal comments . . . as usual.)